Perspective Therapeutics reports $227.8M cash, updates on VMT-α-NET and VMT01 trials

Perspective Therapeutics, Inc.

Preliminary unaudited cash, equivalents and ST investments: $227.8M as of Dec 31, 2024, funding operations into late 2026.
VMT-α-NET: 18 patients dosed in Cohort 2; data submitted to FDA; poster at ASCO-GI Jan 2025.
VMT01: SMC recommends 1.5 mCi dose as monotherapy and with nivolumab; both cohorts open for enrollment.
PSV359 IND filed late 2024; site activation underway, enrollment potentially mid-2025.
Four additional novel assets planned for first-in-human imaging in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.